» Articles » PMID: 7682906

Optimum Treatment of Staphylococcal Infections

Overview
Journal Drugs
Specialty Pharmacology
Date 1993 Mar 1
PMID 7682906
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Serious staphylococcal infections remain a significant clinical problem despite advances in antibacterial therapy. Resistance to penicillin is common and methicillin-resistant staphylococci have become troublesome nosocomial pathogens in many institutions. Penicillinase-resistant penicillins (e.g. flucloxacillin, cloxacillin and oxacillin) are the preferred drugs for all methicillin-susceptible staphylococcal infections, although first generation cephalosporins, beta-lactam/beta-lactamase inhibitor combinations, clindamycin, and occasionally erythromycin and cotrimoxazole (trimethoprim/sulfamethoxazole) are alternatives. Serious infections due to methicillin-resistant staphylococci should be treated with parenteral vancomycin. Teicoplanin, where available, is a suitable alternative. Rifampicin, fusidic acid and some fluoroquinolones may be useful oral alternatives, although resistance develops rapidly if they are used as single agents. Cotrimoxazole and minocycline have also proven useful when strains are susceptible. Staphylococcal toxic shock syndrome often requires aggressive resuscitation and anti-staphylococcal therapy for generally 10 to 14 days. Staphylococcus aureus bacteraemia remains a life-threatening condition which, in all but one-third of cases, is associated with an underlying septic focus such as endocarditis, osteomyelitis or occult abscess. Differentiating between complicated and uncomplicated bacteraemia is critical to define the appropriate treatment regimen. Serious staphylococcal sepsis such as endocarditis and acute osteomyelitis generally requires prolonged (4 to 6 weeks) antibiotic treatment. Coagulase-negative staphylococci are the commonest cause of prosthetic device infection, and generally require prolonged therapy with an agent to which they have proven to be sensitive, e.g. a penicillinase-resistant penicillin or vancomycin. Removal of infected foreign or prosthetic material, and drainage of deep collections remain a critical aspect of all therapy.

Citing Articles

Recent Advances in Antimicrobial Nano-Drug Delivery Systems.

Zong T, Silveira A, Morais J, Sampaio M, Muehlmann L, Zhang J Nanomaterials (Basel). 2022; 12(11).

PMID: 35683711 PMC: 9182179. DOI: 10.3390/nano12111855.


Assessing the impact of a 'bundle of care' approach to bacteraemia in a tertiary hospital.

Green J, Howard J, Shankar A, Clinghan R, Luff T, Birch M Infect Prev Pract. 2021; 2(4):100096.

PMID: 34368726 PMC: 8336039. DOI: 10.1016/j.infpip.2020.100096.


Molecular detection of antimicrobial resistance in local isolates of Staphylococcus epidermidis from urinary tract infections in Faisalabad region of Pakistan.

Farid A, Naz I, Ashraf A, Ali A, Rehman A, Sarwar Y EXCLI J. 2015; 14:697-705.

PMID: 26648821 PMC: 4669908. DOI: 10.17179/excli2015-294.


Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.

Liu C, Lee W, Fung C, Cheng N, Liu C, Yang S Clin Drug Investig. 2014; 12(2):80-7.

PMID: 24610668 DOI: 10.2165/00044011-199612020-00003.


Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K J Clin Microbiol. 2008; 46(9):3042-7.

PMID: 18596146 PMC: 2546754. DOI: 10.1128/JCM.00265-08.


References
1.
Chambers H . Methicillin-resistant staphylococci. Clin Microbiol Rev. 1988; 1(2):173-86. PMC: 358041. DOI: 10.1128/CMR.1.2.173. View

2.
Bluhm G . Pacemaker infections. A clinical study with special reference to prophylactic use of some isoxazolyl penicillins. Acta Med Scand Suppl. 1985; 699:1-62. View

3.
Turnidge J, Lawson P, Munro R, Benn R . A national survey of antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals. Med J Aust. 1989; 150(2):65, 69-72. DOI: 10.5694/j.1326-5377.1989.tb136365.x. View

4.
Sugarman B, Young E . Infections associated with prosthetic devices: magnitude of the problem. Infect Dis Clin North Am. 1989; 3(2):187-98. View

5.
Nolan C, Beaty H . Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med. 1976; 60(4):495-500. DOI: 10.1016/0002-9343(76)90715-4. View